2/2
08:00 am
spry
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing =15 kg to <30 kg
Low
Report
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing =15 kg to <30 kg
1/29
07:41 am
spry
ARS Pharmaceuticals (NASDAQ:SPRY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
ARS Pharmaceuticals (NASDAQ:SPRY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/23
05:06 am
spry
ARS Pharmaceuticals (NASDAQ:SPRY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
ARS Pharmaceuticals (NASDAQ:SPRY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
10:32 am
spry
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use [Yahoo! Finance]
Low
Report
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use [Yahoo! Finance]
1/21
08:00 am
spry
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
Low
Report
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
1/9
12:22 pm
spry
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating [Yahoo! Finance]
Low
Report
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating [Yahoo! Finance]
12/30
08:12 am
spry
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg [Yahoo! Finance]
12/29
08:12 am
spry
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) [Yahoo! Finance]
Low
Report
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) [Yahoo! Finance]
12/29
08:00 am
spry
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
Low
Report
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
12/1
01:35 am
spry
How Recent Developments Are Shaping the Story for ARS Pharmaceuticals According to Analysts [Yahoo! Finance]
Low
Report
How Recent Developments Are Shaping the Story for ARS Pharmaceuticals According to Analysts [Yahoo! Finance]
11/26
08:28 am
spry
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/26
08:00 am
spry
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
Low
Report
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
11/22
07:57 am
spry
ARS Pharmaceuticals (NASDAQ:SPRY) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Medium
Report
ARS Pharmaceuticals (NASDAQ:SPRY) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/16
10:26 pm
spry
Why Analysts See the ARS Pharmaceuticals Story Shifting Amid Changing Growth and Market Risks [Yahoo! Finance]
High
Report
Why Analysts See the ARS Pharmaceuticals Story Shifting Amid Changing Growth and Market Risks [Yahoo! Finance]